| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | <1 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Phase 3 | AstraZeneca | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | <1 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| WATER IV Prostate Cancer | N/A | PROCEPT BioRobotics | <1 mi |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | <1 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | <1 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | <1 mi |
| Registry Study for Radiation Therapy Outcomes | — | Proton Collaborative Group | <1 mi |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | <1 mi |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Phase 3 | Bayer | <1 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | <1 mi |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/2 | Takeda | <1 mi |
| An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | Phase 1 | NextPoint Therapeutics, Inc. | <1 mi |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 2 | Incyte Corporation | <1 mi |
| A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | <1 mi |
| A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Phase 1 | Riboscience, LLC. | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Phase 2 | AstraZeneca | <1 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Phase 1 | ORIC Pharmaceuticals | <1 mi |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors | Phase 1/2 | Perspective Therapeutics | <1 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | <1 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer | Phase 2 | Proton Collaborative Group | <1 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | <1 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | <1 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | Phase 1 | AstraZeneca | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | <1 mi |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | Phase 2 | Eikon Therapeutics | <1 mi |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 1/2 | AstraZeneca | <1 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | <1 mi |
| A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AstraZeneca | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Phase 1/2 | Phanes Therapeutics | <1 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | <1 mi |
| First in Human Study of AZD9592 in Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Phase 2 | AstraZeneca | <1 mi |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | <1 mi |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | BioNTech SE | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | <1 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2 | N/A | Weill Medical College of Cornell University | <1 mi |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Phase 2 | Eli Lilly and Company | <1 mi |
| Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | Phase 1 | NRG Oncology | <1 mi |
| Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | Phase 3 | Johns Hopkins University | <1 mi |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | <1 mi |
| Biospecimen Procurement for Head and Neck Disorders | — | National Cancer Institute (NCI) | <1 mi |
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Phase 3 | Rapamycin Holdings Inc. | <1 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | <1 mi |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | <1 mi |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors | N/A | University of South Florida | <1 mi |
| Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Clinical Trial of Approaches to Prostate Cancer Surgery | N/A | Weill Medical College of Cornell University | <1 mi |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | <1 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | <1 mi |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer | Phase 3 | NRG Oncology | <1 mi |
| Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | Phase 1 | Vaxiion Therapeutics | <1 mi |
| A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | Phase 2 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Proton Radiation Therapy Registry | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | <1 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Blue Light Cystoscopy With Cysview® Registry | — | Photocure | <1 mi |
| Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | Phase 1/2 | University of Maryland, Baltimore | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | <1 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Phase 2 | University of Alabama at Birmingham | <1 mi |
| Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | Phase 1/2 | SignPath Pharma, Inc. | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies | Phase 1 | Catherine Bollard | <1 mi |
| Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | <1 mi |
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | — | AIDS Malignancy Consortium | <1 mi |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | — | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | <1 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Renal Retention in High Grade Upper Tract Urothelial Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Pediatric Radiation Therapy Registry | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy | N/A | Johns Hopkins University | <1 mi |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | Phase 3 | AstraZeneca | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Phase 1 | Sabine Mueller, MD, PhD | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Phase 2 | Healx Limited | <1 mi |
| Gender Related Coping and Survivorship for Genitourinary Cancers | — | Johns Hopkins University | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer | N/A | Johns Hopkins University | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | <1 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Phase 2 | Laura Huppert, MD, BA | <1 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Study in Patients With Breast Cancer Leptomeningeal Metastasis | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | OSE Immunotherapeutics | <1 mi |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | <1 mi |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | <1 mi |
| Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients | — | PrECOG, LLC. | <1 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer | Phase 2 | Georgetown University | <1 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase 2 | AstraZeneca | <1 mi |
| The Ailliance Post-Market Clinical Study | N/A | Medtronic Spinal and Biologics | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | <1 mi |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer | — | Massachusetts General Hospital | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) | Phase 3 | NX Development Corp | <1 mi |
| A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Phase 3 | BeiGene | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | — | Washington University School of Medicine | <1 mi |
| Collection of Tissue Samples for Cancer Research | — | National Cancer Institute (NCI) | <1 mi |
| Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer | Phase 2 | National Institute on Deafness and Other Communication Disorders (NIDCD) | <1 mi |
| Adoptive Cell Therapy Long-term Follow-up (LTFU) Study | Phase 1 | Adaptimmune | <1 mi |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | <1 mi |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | Phase 3 | Daiichi Sankyo | <1 mi |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | <1 mi |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | Phase 2 | AstraZeneca | <1 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | <1 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) | Phase 2 | University of Maryland, Baltimore | <1 mi |
| TERPS Trial for de Novo Oligometastic Prostate Cancer | Phase 2 | University of Maryland, Baltimore | <1 mi |
| LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) | N/A | University of Maryland, Baltimore | <1 mi |
| LITT Followed by Hypofractionated RT for Recurrent Gliomas | N/A | University of Maryland, Baltimore | <1 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| GammaPod Dose Escalation Radiation for Early Stage Breast Cancer | N/A | University of Maryland, Baltimore | <1 mi |
| A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer | Phase 1 | University of Maryland, Baltimore | <1 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | <1 mi |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Takeda | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts | — | Johns Hopkins University | <1 mi |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Phase 2 | Pulmotect, Inc. | <1 mi |
| Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma | — | Case Western Reserve University | <1 mi |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | <1 mi |
| RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | Phase 2 | EpicentRx, Inc. | <1 mi |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | Phase 1/2 | Akouos, Inc. | <1 mi |
| Vaginal Cuff Brachytherapy Fractionation Study | Phase 3 | Kara Romano, MD | <1 mi |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions | — | Ohio State University Comprehensive Cancer Center | <1 mi |
| Measuring Surgical Recovery After Radical Cystectomy | — | M.D. Anderson Cancer Center | <1 mi |
| Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis | Phase 1 | Attralus, Inc. | <1 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | <1 mi |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Phase 2 | MeiraGTx, LLC | <1 mi |
| Intent of Surgery for IPMN | — | NYU Langone Health | <1 mi |
| Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Brenus Pharma | <1 mi |
| Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application | Phase 1/2 | FutureChem | <1 mi |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma | Phase 1 | Poseida Therapeutics, Inc. | <1 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). | Phase 1/2 | Johns Hopkins University | <1 mi |
| Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders | Phase 1/2 | University of Maryland, Baltimore | <1 mi |
| Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study) | — | Johns Hopkins University | <1 mi |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | Phase 2 | Dustin Deming | <1 mi |
| Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | Phase 3 | AbbVie | <1 mi |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | Phase 2 | Rana McKay, MD | <1 mi |
| REMASTer: REcurrent Brain Metastases After SRS Trial | N/A | Monteris Medical | <1 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | <1 mi |
| Caris Biorepository Research Protocol | — | Caris Science, Inc. | <1 mi |
| Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer | — | University of Washington | <1 mi |
| Testing RG1-VLP Vaccine to Prevent HPV-related Cancers | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Effects of Simvastatin on Uterine Leiomyoma Size | Phase 2 | Johns Hopkins University | <1 mi |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Genmab | <1 mi |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | — | Tempus AI | <1 mi |
| A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 1/2 | Imunon | <1 mi |
| Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | — | Century Therapeutics, Inc. | <1 mi |
| A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Simple Bone Cysts in Kids | Phase 3 | The Hospital for Sick Children | <1 mi |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 | Genmab | <1 mi |
| Personalized Treatment in Thyroid Disorders | N/A | Johns Hopkins University | <1 mi |
| Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation | — | Medstar Health Research Institute | <1 mi |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Phase 2/3 | Merck Sharp & Dohme LLC | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| High-Risk Metachronous Oligometastatic Prostate Cancer Trial | Phase 2 | University of Maryland, Baltimore | <1 mi |
| Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe | Phase 1 | Johns Hopkins University | <1 mi |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Phase 1 | Ascentage Pharma Group Inc. | <1 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | <1 mi |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | Phase 2 | Johns Hopkins University | <1 mi |
| Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT | Early 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Transrectal Ultrasound Robot-Assisted Prostate Biopsy | N/A | Johns Hopkins University | <1 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | <1 mi |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | — | Miltenyi Biomedicine GmbH | <1 mi |
| HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | Phase 1/2 | Noah Hahn, M.D. | <1 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | <1 mi |
| PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| REmote Symptom COllection to improVE postopeRative Care | N/A | Medstar Health Research Institute | <1 mi |
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| Spine Radiosurgery for Symptomatic Metastatic Neoplasms | Phase 2 | University of Oklahoma | <1 mi |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | <1 mi |
| Excision of Lymph Node Trial (EXCILYNT) (Mel69) | N/A | Craig L Slingluff, Jr | <1 mi |
| Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy | N/A | Johns Hopkins University | <1 mi |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | Phase 1/2 | SNIPR Biome Aps. | <1 mi |
| Virtual Reality Therapy for Cancer-Treatment Associated Symptoms | N/A | University of Maryland, Baltimore | <1 mi |
| Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue | Phase 2 | University of Maryland, Baltimore | <1 mi |
| HP Pyruvate MRI in Cancers | Phase 1/2 | University of Maryland, Baltimore | <1 mi |
| EsophaCap for the Detection of Early Esophageal Carcinoma | — | Johns Hopkins University | <1 mi |
| Ocular Complications From Cancer Therapy - Patient Registry and Biobank | N/A | University of Maryland, Baltimore | <1 mi |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | Early 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2/3 | Karyopharm Therapeutics Inc | <1 mi |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Diaphragm Structure and Function in Childhood Cancer Survivors | N/A | University of Maryland, Baltimore | <1 mi |
| Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of Healthy Cohort for Early Detection of Cancer | — | Johns Hopkins University | <1 mi |
| 7-Days Water-Only Fasting Trial in Prostate Cancer | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | Phase 1 | Pfizer | <1 mi |
| Primary Tumor Research and Outcomes Network | — | AO Innovation Translation Center | <1 mi |
| A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Kura Oncology, Inc. | <1 mi |
| Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | <1 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | <1 mi |
| A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1/2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | <1 mi |
| The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | Phase 1 | University of Maryland, Baltimore | <1 mi |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | DynamiCure Biotechnology | <1 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | <1 mi |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Physician- and Patient-based Barriers to NGS Testing | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of CHS-114 in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | <1 mi |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | Phase 1 | Pfizer | <1 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | Phase 2 | Daiichi Sankyo | <1 mi |
| Trial of Ixazomib for Kaposi Sarcoma | Phase 2 | AIDS Malignancy Consortium | <1 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | St. Louis University | <1 mi |
| Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | Phase 1 | University of Maryland, Baltimore | <1 mi |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib | Early 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Phase 1 | Dana-Farber Cancer Institute | <1 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | <1 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | <1 mi |
| CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | Phase 2 | University of Maryland, Baltimore | <1 mi |
| Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | <1 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | <1 mi |
| Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | Phase 2 | NATCO Pharma Ltd. | <1 mi |
| Pancreatic Cancer Registry: For Any Person With a Personal or Family History | — | Johns Hopkins University | <1 mi |
| Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | N/A | Second Affiliated Hospital, School of Medicine, Zhejiang University | <1 mi |
| Image-Guided Gynecologic Brachytherapy | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors | Phase 2 | AstraZeneca | <1 mi |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | <1 mi |
| Myriad™ Augmented Soft Tissue Reconstruction Registry | — | Aroa Biosurgery Limited | <1 mi |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | Phase 2 | New York Medical College | <1 mi |
| Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) | Phase 4 | Johns Hopkins University | <1 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | <1 mi |
| Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Phase 2 | Genmab | <1 mi |
| A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Phase 2 | GOG Foundation | <1 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | <1 mi |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study of Treatment for HPV16+ ASC-US or LSIL | Phase 1 | University of Alabama at Birmingham | <1 mi |
| Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | <1 mi |
| The COSMYC Trial (COmbined Suppression of MYC) | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | <1 mi |
| Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | — | University Hospital Freiburg | <1 mi |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Multicenter HomeVENT: Home Values and Experiences Navigation Track | N/A | Johns Hopkins University | <1 mi |
| Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas | Phase 1 | University of Maryland, Baltimore | <1 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | <1 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| Extracorporeal Photopheresis in Sezary Syndrome | — | Oleg E. Akilov, MD, PhD | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma | Phase 3 | Takeda | <1 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | <1 mi |
| A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | Phase 1 | Boston Scientific Corporation | <1 mi |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Phase 2 | Pierre Fabre Medicament | <1 mi |
| Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma | Phase 2 | Manish Patel | <1 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults | Phase 2 | Sabine Mueller, MD, PhD | <1 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Embryonal Tumor With Multilayered Rosettes | Phase 2 | University of California, San Francisco | <1 mi |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early 1 | AIDS Malignancy Consortium | <1 mi |
| Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | Phase 1 | Johns Hopkins University | <1 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | <1 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Phase 3 | Steba Biotech S.A. | <1 mi |
| FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea | Phase 3 | Yale University | <1 mi |
| Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Phase 1 | Arcus Biosciences, Inc. | <1 mi |
| Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors | Phase 1 | Sabine Mueller, MD, PhD | <1 mi |
| A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Phase 1 | MacroGenics | <1 mi |
| IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Phase 1 | Iksuda Therapeutics Ltd. | <1 mi |
| Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeiGene | <1 mi |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | <1 mi |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Exercise in Prostate Cancer | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | Phase 2 | University of Maryland, Baltimore | <1 mi |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase 3 | Mayo Clinic | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome | — | University of Illinois at Chicago | <1 mi |
| StableEyes With Active Neurofeedback | N/A | Johns Hopkins University | <1 mi |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | Phase 1/2 | Amgen | <1 mi |
| PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS | N/A | Boston Children's Hospital | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Phase 1 | Oryzon Genomics S.A. | <1 mi |
| DALY II USA/ MB-CART2019.1 for DLBCL | Phase 2 | Miltenyi Biomedicine GmbH | <1 mi |
| Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms | N/A | Case Comprehensive Cancer Center | <1 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | <1 mi |
| DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | <1 mi |
| NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive Interventions | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | <1 mi |
| Cardiometabolic Screening Program | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| The Cancer of the Pancreas Screening-5 CAPS5)Study | Phase 3 | Johns Hopkins University | <1 mi |
| Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors | N/A | University of Maryland, Baltimore | <1 mi |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Phase 1/2 | AtlasMedx, Incorporated | <1 mi |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants | Phase 1 | AstraZeneca | <1 mi |
| PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | <1 mi |
| Study of LP-184 in Patients With Advanced Solid Tumors | Phase 1/2 | Lantern Pharma Inc. | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis | Phase 2 | Wake Forest University Health Sciences | <1 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | <1 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | Sermonix Pharmaceuticals Inc. | <1 mi |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Phase 2 | Genelux Corporation | <1 mi |
| A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Teligene US | <1 mi |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Phase 1/2 | Verastem, Inc. | <1 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study | — | Tempus AI | <1 mi |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 | AstraZeneca | <1 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | <1 mi |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | <1 mi |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors | Phase 1 | Calico Life Sciences LLC | <1 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | <1 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens | — | Johns Hopkins University | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | <1 mi |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Phase 1/2 | Xencor, Inc. | <1 mi |
| C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics | Phase 4 | Johns Hopkins University | <1 mi |
| First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | Phase 1 | A&G Pharmaceutical Inc. | <1 mi |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Phase 2 | Boehringer Ingelheim | <1 mi |
| Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Phase 3 | InSightec | <1 mi |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies | — | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC | Phase 2/3 | Canadian Cancer Trials Group | <1 mi |
| Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Phase 1 | Boehringer Ingelheim | <1 mi |
| EXoPERT EMERALD Clinical Study | — | EXoPERT | <1 mi |
| Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer | Phase 1 | Impact Biotech Ltd | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| Study of DF1001 in Patients with Advanced Solid Tumors | Phase 1/2 | Dragonfly Therapeutics | <1 mi |
| A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | <1 mi |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | Phase 1 | BeiGene | <1 mi |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | Daiichi Sankyo | <1 mi |
| Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study | Phase 2 | AstraZeneca | <1 mi |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | <1 mi |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 | IDEAYA Biosciences | <1 mi |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | Phase 1 | TopAlliance Biosciences | <1 mi |
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Muhammad Furqan | <1 mi |
| Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier | — | Veracyte, Inc. | <1 mi |
| Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | Phase 2 | University of Maryland, Baltimore | <1 mi |
| A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Phase 1 | Tyra Biosciences, Inc | <1 mi |
| DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma | Phase 1 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | <1 mi |
| Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | — | Bayer | <1 mi |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | <1 mi |
| Multi-analyte Blood Test Clinical Trial | — | Helio Genomics | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune Inc. | <1 mi |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | Phase 3 | AstraZeneca | 8 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | 8 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | 8 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | 8 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 8 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | 8 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 8 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 8 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | 8 mi |
| A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Phase 2 | Candel Therapeutics, Inc. | 8 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | 9 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | 9 mi |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Phase 3 | Telix Pharmaceuticals (Innovations) Pty Limited | 9 mi |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Fusion Pharmaceuticals Inc. | 9 mi |
| GammaPod Registry and Quality of Life Nomogram | — | University of Maryland, Baltimore | 9 mi |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Phase 1 | Cellectar Biosciences, Inc. | 9 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | 9 mi |
| Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer | — | University of Maryland, Baltimore | 9 mi |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Phase 1 | Abdera Therapeutics Inc. | 9 mi |
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | Phase 1 | Orano Med LLC | 9 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 9 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | 9 mi |
| Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. | N/A | Pacific Edge Limited | 9 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 9 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | 9 mi |
| Integrated Cancer Repository for Cancer Research | — | University of Nebraska | 11 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | 12 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | 13 mi |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | 13 mi |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Zenith Epigenetics | 13 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | 13 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | 13 mi |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | 13 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | 13 mi |
| A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC) | Phase 2 | SCRI Development Innovations, LLC | 13 mi |
| ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | — | argenx | 13 mi |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Phase 2 | SCRI Development Innovations, LLC | 13 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | 13 mi |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Phase 3 | Verrica Pharmaceuticals Inc. | 15 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | 18 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | 22 mi |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 23 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | 23 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | 23 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 23 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | 23 mi |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | 23 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | 23 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 23 mi |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | — | Blueprint Medicines Corporation | 24 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | 26 mi |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | 29 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | 30 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 30 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | 30 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | 30 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | 30 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | 30 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | 30 mi |
| MYLUNG Consortium Part 3: Observational Study | — | US Oncology Research | 30 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | 30 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 30 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | 30 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | 30 mi |
| Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Phase 2/3 | Kartos Therapeutics, Inc. | 30 mi |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Phase 3 | Genelux Corporation | 30 mi |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Phase 2 | Nurix Therapeutics, Inc. | 30 mi |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Phase 1 | Bio-Path Holdings, Inc. | 30 mi |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Phase 3 | Daiichi Sankyo | 30 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | 30 mi |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | AbbVie | 30 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | 30 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | 30 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 32 mi |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Phase 1 | Pfizer | 32 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Phase 1/2 | Genprex, Inc. | 32 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | 32 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | 32 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | 32 mi |
| Rare Tumors and Cancer Predisposition in Individuals and Families | — | National Cancer Institute (NCI) | 32 mi |
| DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study | — | National Cancer Institute (NCI) | 32 mi |
| Cancer in Inherited Bone Marrow Failure Syndromes | — | National Cancer Institute (NCI) | 32 mi |
| MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other | Phase 2 | Sunstone Medical | 32 mi |
| To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | Phase 2 | Stamford Pharmaceuticals, Inc. | 32 mi |
| Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer | Phase 2 | Sunstone Medical | 32 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | 32 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 34 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | 34 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | 34 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | 34 mi |
| Study of NEO-201 in Solid Tumors Expansion Cohorts | Phase 1/2 | Precision Biologics, Inc | 34 mi |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Shanghai Junshi Bioscience Co., Ltd. | 34 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | 34 mi |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | Phase 3 | GlaxoSmithKline | 34 mi |
| A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... | N/A | National Cancer Institute (NCI) | 34 mi |
| Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer | N/A | Adam S. Kibel, MD | 34 mi |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Hoffmann-La Roche | 34 mi |
| Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies | — | National Cancer Institute (NCI) | 34 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | 34 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | 34 mi |
| National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period. | Phase 2 | Genentech, Inc. | 34 mi |
| Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia | — | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Incyte Corporation | 34 mi |
| Diagnosing and Treating Low Blood Sugar Levels | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease | — | National Cancer Institute (NCI) | 34 mi |
| PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Phase 2 | Precigen, Inc | 34 mi |
| Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue | — | National Cancer Institute (NCI) | 34 mi |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | Phase 1/2 | Crinetics Pharmaceuticals Inc. | 34 mi |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | 34 mi |
| NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Diagnosis of Pheochromocytoma | Phase 1 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 34 mi |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Phase 3 | Novartis Pharmaceuticals | 34 mi |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes | — | National Cancer Institute (NCI) | 34 mi |
| Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune) | — | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Phase 3 | Novartis Pharmaceuticals | 34 mi |
| Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Study of Proteus Syndrome and Related Congenital Disorders | — | National Human Genome Research Institute (NHGRI) | 34 mi |
| Children and Adults With Chordoma | — | National Cancer Institute (NCI) | 34 mi |
| Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy | — | National Cancer Institute (NCI) | 34 mi |
| A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies | — | National Cancer Institute (NCI) | 34 mi |
| Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Natural History Study of Bone and Mineral Disorders | — | National Institute of Dental and Craniofacial Research (NIDCR) | 34 mi |
| Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders | — | National Cancer Institute (NCI) | 34 mi |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer | Phase 1 | National Institute of Dental and Craniofacial Research (NIDCR) | 34 mi |
| Natural History Study of Parathyroid Disorders | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| A Natural History Study of Children and Adults With Olfactory Neuroblastoma | — | National Cancer Institute (NCI) | 34 mi |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL | — | National Cancer Institute (NCI) | 34 mi |
| Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms | — | National Cancer Institute (NCI) | 34 mi |
| Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors | Phase 3 | Mayo Clinic | 34 mi |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Clonal Evolution in Follicular Lymphoma | — | National Cancer Institute (NCI) | 34 mi |
| Natural History Study of Patients With Neurofibromatosis Type 2 | — | National Institute of Neurological Disorders and Stroke (NINDS) | 34 mi |
| Tissue Collection for Studies of Lymph Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Natural History of KSHV-Associated Multicentric Castleman s Disease | — | National Cancer Institute (NCI) | 34 mi |
| Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants | — | National Cancer Institute (NCI) | 34 mi |
| Sample Collection and Tracking for the Developmental Therapeutics Clinic | — | National Cancer Institute (NCI) | 34 mi |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| 18F-Fluciclovine PET/CT in Multiple Myeloma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Study of Factors Regulating Mast Cell Proliferation | — | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy | — | National Cancer Institute (NCI) | 34 mi |
| The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | Phase 1 | Alessa Therapeutics Inc. | 34 mi |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | 34 mi |
| An Investigation of Pituitary Tumors and Related Hypothalmic Disorders | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 34 mi |
| Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer | N/A | National Cancer Institute (NCI) | 34 mi |
| Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies | — | National Cancer Institute (NCI) | 34 mi |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | Phase 3 | SWOG Cancer Research Network | 34 mi |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS) | — | Northwestern University | 34 mi |
| Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) | — | National Cancer Institute (NCI) | 34 mi |
| Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| The PCOS Challenge Study | — | PCOS Challenge: The National Polycystic Ovary Syndrome Association | 34 mi |
| Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | Phase 2 | Memorial Sloan Kettering Cancer Center | 34 mi |
| Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| A Phase I Study of Mozobil in the Treatment of Patients With WHIMS | Phase 1/2 | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy | — | National Cancer Institute (NCI) | 34 mi |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists | Phase 1 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant | — | National Cancer Institute (NCI) | 34 mi |
| Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma | — | National Cancer Institute (NCI) | 34 mi |
| Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery | N/A | National Institute of Neurological Disorders and Stroke (NINDS) | 34 mi |
| Clinical and Genetic Studies of Li-Fraumeni Syndrome | — | National Cancer Institute (NCI) | 34 mi |
| Longitudinal Studies of Patient With FPDMM | — | National Human Genome Research Institute (NHGRI) | 34 mi |
| Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment | — | National Cancer Institute (NCI) | 34 mi |
| En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device | — | National Cancer Institute (NCI) | 34 mi |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study | — | National Cancer Institute (NCI) | 34 mi |
| Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome | — | National Cancer Institute (NCI) | 34 mi |
| Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors | — | National Cancer Institute (NCI) | 34 mi |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | — | National Cancer Institute (NCI) | 34 mi |
| Studies of Dermatologic Diseases Biospecimen Acquisition Protocol | — | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 34 mi |
| Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Psychological Benefits of a Normalized Camping Experience for Children With Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Studies on Tumors of the Thyroid | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue | — | National Cancer Institute (NCI) | 34 mi |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Men at High Genetic Risk for Prostate Cancer | — | National Cancer Institute (NCI) | 34 mi |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Zopa Retreatment and Vector Shedding in Adults With RRP | Phase 4 | Precigen, Inc | 34 mi |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Studying TAK-243 in Patients With Advanced Cancer | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Natural History Study of Kaposi Sarcoma | — | National Cancer Institute (NCI) | 34 mi |
| A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients | N/A | National Institutes of Health Clinical Center (CC) | 34 mi |
| Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | Phase 1/2 | CellCentric Ltd. | 34 mi |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | Phase 2 | Christian Hinrichs | 34 mi |
| Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS | — | National Cancer Institute (NCI) | 34 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 34 mi |
| Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Natural History Study of Children and Adults With Medullary Thyroid Cancer | — | National Cancer Institute (NCI) | 34 mi |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | Phase 3 | Grifols Therapeutics LLC | 34 mi |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 34 mi |
| PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors | N/A | National Cancer Institute (NCI) | 34 mi |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | Phase 2/3 | Eikon Therapeutics | 34 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 34 mi |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| NIDCD Otolaryngology Clinical Protocol Biospecimen Bank | — | National Institute on Deafness and Other Communication Disorders (NIDCD) | 34 mi |
| A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Phase 1 | Oncotherapeutics | 34 mi |
| Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | Phase 2 | Memorial Sloan Kettering Cancer Center | 34 mi |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 3 | Loxo Oncology, Inc. | 34 mi |
| PT-112 in Subjects With Thymoma and Thymic Carcinoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Precision-Based Genomics in Prostate Cancer | — | National Cancer Institute (NCI) | 34 mi |
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism | Phase 3 | Rezolute | 34 mi |
| Natural History of Familial Carcinoid Tumor | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) | N/A | National Cancer Institute (NCI) | 34 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | 34 mi |
| Collection of Blood From Patients With Prostate Cancer | — | National Cancer Institute (NCI) | 34 mi |
| IDENTIFY Study: Natural History of Maternal Neoplasia | N/A | National Human Genome Research Institute (NHGRI) | 34 mi |
| SPEARHEAD-3 Pediatric Study | Phase 1/2 | USWM CT, LLC | 34 mi |
| Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Tumor Related Epilepsy | — | National Institute of Neurological Disorders and Stroke (NINDS) | 34 mi |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| MK-7075 (Miransertib) in Proteus Syndrome | Phase 2 | National Human Genome Research Institute (NHGRI) | 34 mi |
| Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera | Phase 3 | Italfarmaco | 34 mi |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Natural History Study of GATA2 Deficiency and Related Disorders | — | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays | — | Tempus AI | 34 mi |
| Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 34 mi |
| The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease | — | National Cancer Institute (NCI) | 34 mi |
| Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease | — | National Cancer Institute (NCI) | 34 mi |
| Data Collection Study of Pediatric and Adolescent Gynecology Conditions | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 34 mi |
| Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis | — | National Cancer Institute (NCI) | 34 mi |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | 34 mi |
| Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib | Early 1 | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | Phase 1/2 | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing | — | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 34 mi |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Genetic Studies of Chronic Active Epstein-Barr Disease | — | National Institute of Allergy and Infectious Diseases (NIAID) | 34 mi |
| Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Phase 3 | BeOne Medicines | 34 mi |
| Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 2 | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | 34 mi |
| 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Phase 1 | Jazz Pharmaceuticals | 34 mi |
| A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies | — | Tempus AI | 34 mi |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Vaccine Responses in Patients With B Cell Malignancies | Phase 4 | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme | — | National Cancer Institute (NCI) | 34 mi |
| Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer | N/A | National Cancer Institute (NCI) | 34 mi |
| A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | GigaGen, Inc. | 34 mi |
| A Natural History Study of Metabolic Sizing in Health and Disease | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 34 mi |
| Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial | N/A | National Cancer Institute (NCI) | 34 mi |
| Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia | — | National Cancer Institute (NCI) | 34 mi |
| Evaluation and Treatment of Neurosurgical Disorders | — | National Institute of Neurological Disorders and Stroke (NINDS) | 34 mi |
| Patient-Centered Assessment of Symptoms and Outcomes | — | National Center for Complementary and Integrative Health (NCCIH) | 34 mi |
| Study of Skin Tumors in Tuberous Sclerosis | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | 34 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | 34 mi |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Phase 2 | The Methodist Hospital Research Institute | 34 mi |
| Genomic Services Research Program | — | National Human Genome Research Institute (NHGRI) | 34 mi |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | N/A | Novian Health Inc. | 34 mi |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) | N/A | National Cancer Institute (NCI) | 34 mi |
| Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) | N/A | University Hospital, Basel, Switzerland | 34 mi |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | — | National Cancer Institute (NCI) | 34 mi |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Evaluation for NCI Surgery Branch Clinical Research Protocols | — | National Cancer Institute (NCI) | 34 mi |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer | — | National Cancer Institute (NCI) | 34 mi |
| Rapid Autopsy and Procurement of Cancer Tissue | — | National Cancer Institute (NCI) | 34 mi |
| Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | 34 mi |
| Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors | Phase 1 | Ankyra Therapeutics, Inc | 34 mi |
| Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis | — | National Cancer Institute (NCI) | 34 mi |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Phase 3 | Zai Lab (Shanghai) Co., Ltd. | 34 mi |
| Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors | — | National Cancer Institute (NCI) | 34 mi |
| T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Dabrafenib and/or Trametinib Rollover Study | Phase 4 | Novartis Pharmaceuticals | 34 mi |
| Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining | — | National Cancer Institute (NCI) | 34 mi |
| Study of the Disease Process of Lymphangioleiomyomatosis | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma | — | National Cancer Institute (NCI) | 34 mi |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | Phase 1/2 | National Cancer Institute (NCI) | 34 mi |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies | — | National Cancer Institute (NCI) | 34 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | 34 mi |
| Role of Genetic Factors in the Development of Lung Disease | — | National Heart, Lung, and Blood Institute (NHLBI) | 34 mi |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | Phase 1 | National Cancer Institute (NCI) | 34 mi |
| Collection of Blood From Patients With Cancer | — | National Cancer Institute (NCI) | 34 mi |
| PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | Phase 2 | National Cancer Institute (NCI) | 34 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | 36 mi |
| Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy | N/A | Georgetown University | 36 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | 36 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | 36 mi |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | 36 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | 36 mi |
| A Study of YL201 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 36 mi |
| A Study of EP0031 in Patients With Advanced RET-altered Malignancies | Phase 1/2 | Ellipses Pharma | 36 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | 36 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | 36 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | 36 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | 36 mi |
| Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 36 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | 36 mi |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Phase 1 | Boehringer Ingelheim | 36 mi |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Phase 1/2 | Institut de Recherches Internationales Servier | 36 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | 36 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | 36 mi |
| A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Phase 3 | Taiho Oncology, Inc. | 36 mi |
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | Phase 3 | Nuvation Bio Inc. | 36 mi |
| A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | Phase 2 | Amgen | 36 mi |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | Phase 1/2 | EMD Serono Research & Development Institute, Inc. | 36 mi |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | Phase 1/2 | Synthekine | 36 mi |
| Study of XB010 in Subjects With Solid Tumors | Phase 1 | Exelixis | 36 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | 36 mi |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Phase 1/2 | Tango Therapeutics, Inc. | 36 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | 36 mi |
| A Study of PHN-012 in Patients With Advanced Solid Tumors | Phase 1 | Pheon Therapeutics | 36 mi |
| Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women | N/A | ISA Associates, Inc. | 36 mi |
| Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer | N/A | Georgetown University | 36 mi |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Phase 3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 36 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | 36 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | 36 mi |
| A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | Phase 1/2 | Seattle Children's Hospital | 36 mi |
| Acute Concussion and Melatonin | Phase 2 | Children's National Research Institute | 36 mi |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Phase 2 | VA Office of Research and Development | 36 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Phase 2 | Merck Sharp & Dohme LLC | 36 mi |
| MuSK Myasthenia 1000 Study | — | Myasthenia Gravis Rare Disease Network | 36 mi |
| DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy | Phase 1 | Boehringer Ingelheim | 36 mi |
| Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma | N/A | University of California, San Francisco | 36 mi |
| ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | 36 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | 36 mi |
| Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | Phase 2 | Diwakar Davar | 36 mi |
| De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers | N/A | Georgetown University | 36 mi |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | BioNTech SE | 36 mi |
| Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies | Phase 2 | Hackensack Meridian Health | 36 mi |
| Targeted Pediatric High-Grade Glioma Therapy | — | Nationwide Children's Hospital | 36 mi |
| First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 36 mi |
| Pre-operative Hypofractionated Proton Therapy | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 36 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | 36 mi |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | Phase 1 | National Cancer Institute (NCI) | 36 mi |
| Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients with High Risk Solid Tumors | Phase 1 | Children's National Research Institute | 36 mi |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | Phase 2 | NRG Oncology | 36 mi |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 36 mi |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | Phase 1 | Valent Technologies, LLC | 36 mi |
| A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Phase 2 | Nationwide Children's Hospital | 36 mi |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Phase 1/2 | Merck Sharp & Dohme LLC | 36 mi |
| PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | Phase 3 | Alexion Pharmaceuticals, Inc. | 36 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | 36 mi |
| ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Phase 2 | Nationwide Children's Hospital | 36 mi |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | 36 mi |
| Assessment of Tubal Occlusion During Minimally Invasive Myomectomy | N/A | Medstar Health Research Institute | 36 mi |
| Study of Olutasidenib and Temozolomide in HGG | Phase 2 | Rigel Pharmaceuticals | 36 mi |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | Phase 1/2 | Merck Sharp & Dohme LLC | 36 mi |
| MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | Phase 1/2 | Ann & Robert H Lurie Children's Hospital of Chicago | 36 mi |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | Phase 1/2 | St. Jude Children's Research Hospital | 36 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | 36 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 36 mi |
| International Rare Brain Tumor Registry | — | Children's National Research Institute | 36 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | 36 mi |
| Feasibility/Acceptability of Attentional-Control Training in Survivors | N/A | Children's National Research Institute | 36 mi |
| An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study | — | University of Rochester NCORP Research Base | 36 mi |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | 36 mi |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1/2 | ModernaTX, Inc. | 36 mi |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Phase 1 | Children's Oncology Group | 36 mi |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | — | Novartis Pharmaceuticals | 36 mi |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | Phase 2 | Fred Hutchinson Cancer Center | 36 mi |
| Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN) | N/A | Medstar Health Research Institute | 36 mi |
| Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | N/A | Dartmouth-Hitchcock Medical Center | 36 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | 36 mi |
| A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | Phase 2 | AstraZeneca | 36 mi |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | Massachusetts General Hospital | 36 mi |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | 36 mi |
| A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | 36 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | 36 mi |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Phase 2/3 | Panbela Therapeutics, Inc. | 36 mi |
| Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma | — | Children's National Research Institute | 36 mi |
| Castrate Resistant Prostate Cancer Enhertu Therapy | Phase 2 | Washington D.C. Veterans Affairs Medical Center | 36 mi |
| Pilot Imaging Study of Leukemia | Phase 1 | University of Oklahoma | 36 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 36 mi |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | Phase 1/2 | Hackensack Meridian Health | 36 mi |
| Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers | Phase 2 | National Cancer Institute (NCI) | 36 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | 36 mi |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Phase 1/2 | Therapeutic Advances in Childhood Leukemia Consortium | 36 mi |
| Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Phase 2 | Nationwide Children's Hospital | 36 mi |
| MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | 36 mi |
| Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors | N/A | Georgetown University | 36 mi |
| Massage Impact on Sleep in Pediatric Oncology | N/A | Children's Hospital of Philadelphia | 36 mi |
| A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Early 1 | Nationwide Children's Hospital | 36 mi |
| Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer | — | Wake Forest University Health Sciences | 36 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | 36 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | 36 mi |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Phase 2 | National Cancer Institute (NCI) | 36 mi |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 1/2 | InSightec | 36 mi |
| Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | Phase 2 | Hackensack Meridian Health | 36 mi |
| Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | Phase 1 | Vanda Pharmaceuticals | 36 mi |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Phase 2 | Vyriad, Inc. | 36 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | 36 mi |
| Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG | — | Johns Hopkins University | 36 mi |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Phase 1/2 | Merck Sharp & Dohme LLC | 36 mi |
| Mosaic Trial for Stem Cell Transplant Recipients | N/A | Northwestern University | 36 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | 36 mi |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/3 | Novartis Pharmaceuticals | 36 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | 36 mi |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | Phase 1/2 | Children's Oncology Group | 36 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | 36 mi |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | 36 mi |
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Phase 2 | Georgetown University | 36 mi |
| Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | Phase 3 | Alliance for Clinical Trials in Oncology | 36 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | 36 mi |
| Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) | Phase 1 | Children's National Research Institute | 36 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | 36 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | 36 mi |
| NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | Phase 1 | Georgetown University | 36 mi |
| Visual Plasticity Following Brain Lesions | N/A | Georgetown University | 36 mi |
| A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects | N/A | InSightec | 36 mi |
| Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 36 mi |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | Phase 1/2 | National Cancer Institute (NCI) | 36 mi |
| F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors) | N/A | Georgetown University | 36 mi |
| Addressing Genomic Disparities in Cancer Survivors | N/A | Rutgers, The State University of New Jersey | 36 mi |
| Pembrolizumab and Lenvatinib in Advanced Cervical Cancer | Phase 2 | Georgetown University | 36 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | 36 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | 36 mi |
| Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) | Phase 1 | Children's National Research Institute | 36 mi |
| Phase IB/II of CPX-351 for Relapse Prevention in AML | Phase 1/2 | Georgetown University | 36 mi |
| Digital Intervention for Symptom Management in Cancer and Opioid Sparing Using Virtual Reality (DISCOVR) Study | N/A | Medstar Health Research Institute | 36 mi |
| A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer | Phase 3 | BioNTech SE | 36 mi |
| Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients | N/A | Georgetown University | 36 mi |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase 2 | Nationwide Children's Hospital | 36 mi |
| Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia | N/A | Children's National Research Institute | 36 mi |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Phase 2 | Ana C Garrido-Castro, MD | 36 mi |
| The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | N/A | Georgetown University | 36 mi |
| Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters) | N/A | Virginia Commonwealth University | 36 mi |
| Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer | Phase 2 | Abramson Cancer Center at Penn Medicine | 36 mi |
| ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies | Phase 1/2 | ALX Oncology Inc. | 36 mi |
| Improving Genetic Counseling for BRCA+ Mothers | N/A | Georgetown University | 36 mi |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | 36 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | 36 mi |
| Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) | Phase 2 | George Washington University | 36 mi |
| Identifying Patterns in the Breath of Individuals With Breast Cancer | — | Breathe BioMedical Inc | 36 mi |
| CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing | N/A | Georgetown University | 36 mi |
| X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma | Phase 1 | Immunolight, LLC | 36 mi |
| Older Breast Cancer Patients: Risk for Cognitive Decline | — | Georgetown University | 36 mi |
| Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming | N/A | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 36 mi |
| RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer | Phase 1/2 | Georgetown University | 36 mi |
| Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | Phase 2 | Criterium, Inc. | 36 mi |
| ETHAN - ET for Male BC | Phase 2 | Jose Pablo Leone | 36 mi |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | 36 mi |
| Gilteritinib for the Treatment of ALK NSCLC | Phase 1 | University of Michigan Rogel Cancer Center | 36 mi |
| Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | Phase 2 | Hackensack Meridian Health | 36 mi |
| Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer | Phase 2 | Georgetown University | 36 mi |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia | — | University of Rochester | 36 mi |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Phase 1 | Pfizer | 36 mi |
| FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | Phase 1/2 | Pierre Fabre Medicament | 36 mi |
| Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement | Phase 2 | Georgetown University | 36 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | 36 mi |
| Repositioning Immunotherapy in VetArans With Lung Cancer | Phase 2 | VA Office of Research and Development | 36 mi |
| A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening | N/A | Georgetown University | 36 mi |
| Erector Spinae Block for Thoracic Surgery | Phase 4 | George Washington University | 36 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | 36 mi |
| Tobacco Education and Lung Health Study (TEAL) | Phase 3 | Georgetown University | 36 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | 36 mi |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Phase 1/2 | VM Oncology, LLC | 36 mi |
| Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | N/A | AIDS Malignancy Consortium | 36 mi |
| Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery | Phase 3 | George Washington University | 36 mi |
| Evaluating Novel Therapies in ctDNA Positive GI Cancers | Phase 3 | Georgetown University | 36 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | 36 mi |
| Cancer Experience Registry (CER) for Cancer Patients and Caregivers | — | Cancer Support Community, Research and Training Institute, Philadelphia | 36 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Phase 1/2 | Hoffmann-La Roche | 36 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | 39 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | 39 mi |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | Phase 1/2 | Vivace Therapeutics, Inc | 39 mi |
| Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | BicycleTx Limited | 39 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | 39 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | 41 mi |
| Activity Coaching During Pelvic Radiation Therapy | N/A | Inova Health Care Services | 41 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | 41 mi |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | 41 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 41 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | 41 mi |
| The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) | Phase 2 | Inova Health Care Services | 41 mi |
| A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | Phase 2/3 | Inova Health Care Services | 41 mi |
| Bright Ideas - CIN Feasibility Study | N/A | The Hospital for Sick Children | 41 mi |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | NextCure, Inc. | 41 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | 43 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | 43 mi |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | BioNTech SE | 44 mi |
| TEMPUS ARIES: A Biobank Registry Platform Study in Oncology | — | Tempus AI | 44 mi |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Phase 2/3 | BioNTech SE | 44 mi |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | — | Elephas | 44 mi |
| Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies | — | Elephas | 44 mi |
| A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass | — | Cleo Diagnostics Ltd | 45 mi |
| National Mammography Database | — | American College of Radiology | 45 mi |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | Incyte Corporation | 47 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 47 mi |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | 47 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | 47 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | 47 mi |
| WellSpan-THRIVE Cancer QOL Study | — | WellSpan Health | 47 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 47 mi |
| Customized TULSA-PRO Ablation Registry | — | Profound Medical Inc. | 47 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | 47 mi |
| Use of an Intrauterine Manipulator and Its Correlation with Positive Peritoneal Cytology in Early Stage Endometrial Cancers | N/A | WellSpan Health | 47 mi |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | 47 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | 47 mi |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | AbbVie | 47 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 47 mi |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | 47 mi |
| Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment | Phase 3 | University of Rochester NCORP Research Base | 47 mi |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | Phase 3 | SWOG Cancer Research Network | 47 mi |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | 47 mi |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | N/A | Eastern Cooperative Oncology Group | 47 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | 47 mi |
| A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Phase 1 | Boehringer Ingelheim | 48 mi |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Phase 1/2 | Merus B.V. | 48 mi |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | 48 mi |
| A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | OnCusp Therapeutics, Inc. | 48 mi |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Avistone Biotechnology Co., Ltd. | 48 mi |
| Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | Phase 1 | Gilead Sciences | 48 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | 48 mi |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Phase 1/2 | Deciphera Pharmaceuticals, LLC | 48 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 48 mi |
| A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | Phase 2 | Merck Sharp & Dohme LLC | 48 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | 48 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | Phase 1/2 | Shenzhen Ionova Life Sciences Co., Ltd. | 48 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | 48 mi |
| A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy | — | Inova Health Care Services | 48 mi |
| Study of PYX-201 in Solid Tumors | Phase 1 | Pyxis Oncology, Inc | 48 mi |
| PAS-004 in Patients With Advanced Solid Tumors | Phase 1 | Pasithea Therapeutics Corp. | 48 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Phase 1 | Kumquat Biosciences Inc. | 48 mi |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Phase 3 | Soligenix | 48 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | Phase 1/2 | Nimbus Wadjet, Inc. | 48 mi |
| A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 48 mi |
| Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | Phase 1 | BeiGene | 48 mi |
| First in Human, Dose Escalation Study of AN4005 | Phase 1 | Adlai Nortye Biopharma Co., Ltd. | 48 mi |
| Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 48 mi |
| Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System | N/A | Inova Health Care Services | 48 mi |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase 1/2 | Corbus Pharmaceuticals Inc. | 48 mi |
| Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 48 mi |
| An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Teva Branded Pharmaceutical Products R&D, Inc. | 48 mi |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Phase 2 | BioNTech SE | 48 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | 48 mi |
| A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | Phase 1 | Chugai Pharmaceutical | 48 mi |
| A Study of ZL-1310 in Participants With Selected Solid Tumors | Phase 1/2 | Zai Lab (Shanghai) Co., Ltd. | 48 mi |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors | Phase 1 | Janssen Research & Development, LLC | 48 mi |
| A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 48 mi |
| A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors | Phase 1 | DualityBio Inc. | 48 mi |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer | Phase 1 | Cartography Biosciences | 48 mi |
| First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 48 mi |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Phase 3 | Novartis Pharmaceuticals | 48 mi |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Phase 1 | Biohaven Therapeutics Ltd. | 48 mi |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Phase 1 | ADC Therapeutics S.A. | 48 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | 48 mi |
| A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | Phase 1/2 | Carrick Therapeutics Limited | 48 mi |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Phase 1/2 | Indapta Therapeutics, INC. | 48 mi |
| NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Phase 1/2 | Novita Pharmaceuticals, Inc. | 48 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | 48 mi |
| A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) | Phase 1 | Merck Sharp & Dohme LLC | 48 mi |
| Study of GS-5319 in Adults With Solid Tumors | Phase 1 | Gilead Sciences | 48 mi |
| A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 | Daiichi Sankyo | 48 mi |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Phase 1 | Merck Sharp & Dohme LLC | 48 mi |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | Phase 2 | Corcept Therapeutics | 48 mi |
| The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer | Phase 2 | Inova Health Care Services | 48 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | 48 mi |
| Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Phase 1/2 | Pyxis Oncology, Inc | 48 mi |
| A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy | Phase 1 | AstraZeneca | 48 mi |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase 1/2 | Corbus Pharmaceuticals Inc. | 48 mi |
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 48 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | 48 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | 48 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 48 mi |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Erasca, Inc. | 48 mi |
| A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | Phase 1/2 | 1ST Biotherapeutics, Inc. | 48 mi |
| First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies | Phase 1/2 | VelaVigo Bio Inc | 48 mi |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | 48 mi |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Phase 1 | Neomorph, Inc | 48 mi |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies | Phase 1/2 | Ipsen | 48 mi |
| Study of SGR-3515 In Participants With Advanced Solid Tumors. | Phase 1 | Schrödinger, Inc. | 48 mi |
| A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies | Phase 1 | Compugen Ltd | 48 mi |
| A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | 48 mi |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Phase 1/2 | ImmVira Pharma Co. Ltd | 48 mi |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | 48 mi |
| Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors | Phase 1/2 | Everest Medicines (Beijing) Co., Ltd. | 48 mi |
| A Study in Patients With Advanced Cancers | Phase 1/2 | BiOneCure Therapeutics Inc. | 48 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | SystImmune Inc. | 48 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | 48 mi |
| A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases | Phase 1 | A2A Pharmaceuticals Inc. | 48 mi |
| A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors | Phase 1 | PAQ Therapeutics, Inc. | 48 mi |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | 48 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | 48 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | 48 mi |
| Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 1 | Bristol-Myers Squibb | 48 mi |
| A Study of HS-20110 in Participants With Advanced Solid Tumors | Phase 1 | Hansoh BioMedical R&D Company | 48 mi |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Hoffmann-La Roche | 48 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 3 | Revolution Medicines, Inc. | 48 mi |
| A Study of LM-24C5 For Advanced Solid Tumors | Phase 1/2 | LaNova Medicines Limited | 48 mi |
| First in Human Study of TORL-1-23 in Participants With Advanced Cancer | Phase 1 | TORL Biotherapeutics, LLC | 48 mi |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | 48 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | 48 mi |
| ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC | Phase 1 | ORIC Pharmaceuticals | 48 mi |
| Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy | N/A | Proton Collaborative Group | 48 mi |
| DPTX3186 in Wnt Pathway Activated Solid Tumors | Phase 1 | Dewpoint Therapeutics | 48 mi |
| A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | Phase 1 | FoRx Therapeutics AG | 48 mi |
| A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | Phase 2/3 | AbbVie | 48 mi |
| Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | Phase 1 | Tagworks Pharmaceuticals BV | 48 mi |
| A Study of ASP1002 in Adults for Treatment of Solid Tumors | Phase 1 | Astellas Pharma Global Development, Inc. | 48 mi |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phase 1/2 | Phanes Therapeutics | 48 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | 48 mi |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | 48 mi |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer | Phase 1 | AbbVie | 48 mi |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | Phase 1 | AbbVie | 48 mi |
| A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors | Phase 1 | Adcentrx Therapeutics | 48 mi |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | 48 mi |
| Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Phase 1/2 | Pathos AI, Inc. | 48 mi |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | 48 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | 48 mi |
| A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | Phase 1 | Peel Therapeutics Inc | 48 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | 48 mi |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Phase 1/2 | Effector Therapeutics | 48 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | 48 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | 48 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | 48 mi |
| A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | Phase 1 | Stemline Therapeutics, Inc. | 48 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | 48 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | 48 mi |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Phase 3 | Daiichi Sankyo | 48 mi |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | Phase 2 | Proton Collaborative Group | 48 mi |
| A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Phase 1/2 | Ipsen | 48 mi |
| A Study of ZW191 in Participants With Solid Tumors | Phase 1 | Zymeworks BC Inc. | 48 mi |
| A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | 48 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors | Phase 1 | Shanghai Allink Biotherapeutics Co., Ltd. | 48 mi |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | Phase 1 | HiberCell, Inc. | 48 mi |
| Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture | N/A | Inova Health Care Services | 48 mi |
| Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) | Phase 1 | Rgenta Therapeutics Inc | 48 mi |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | Phase 1/2 | Ipsen | 48 mi |
| A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | Phase 1/2 | Ipsen | 48 mi |
| A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Amgen | 48 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | 48 mi |
| Pre-Operative Window of ET to Inform RT Decisions (POWER II) | Phase 3 | University of Virginia | 48 mi |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Phase 1/2 | 858 Therapeutics, Inc. | 48 mi |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Phase 1 | Accent Therapeutics | 48 mi |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Phase 1 | Biotheryx, Inc. | 48 mi |
| Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | Phase 1/2 | Merck Sharp & Dohme LLC | 48 mi |
| Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Phase 1/2 | Ellipses Pharma | 48 mi |
| Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy | Phase 3 | Proton Collaborative Group | 48 mi |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | 48 mi |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | 48 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 48 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | 48 mi |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | Phase 1 | OnKure, Inc. | 48 mi |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Phase 2 | AstraZeneca | 48 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | 48 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | 48 mi |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Phase 1/2 | Eikon Therapeutics | 48 mi |
| A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Phase 1 | Hefei TG ImmunoPharma Co., Ltd. | 48 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | 48 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | 48 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | 48 mi |
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer | Phase 1 | Boundless Bio, Inc. | 48 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | 48 mi |
| Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Phase 3 | Laekna Limited | 48 mi |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Phase 1/2 | Ensem Therapeutics | 48 mi |
| Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics | Phase 1 | University of Utah | 48 mi |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | 48 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | 48 mi |
| A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors | Phase 1 | Totus Medicines | 48 mi |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Phase 1 | Cogent Biosciences, Inc. | 48 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 48 mi |
| A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | Phase 1/2 | Yuhan Corporation | 48 mi |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Phase 1/2 | Tasca Therapeutics | 48 mi |
| A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer | Phase 1/2 | Janssen Research & Development, LLC | 48 mi |
| A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | Phase 2 | Wayshine Biopharm, Inc. | 48 mi |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | 48 mi |
| Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. | Phase 1/2 | Chipscreen Biosciences, Ltd. | 48 mi |
| A Study of DM005 in Patients With Advanced Solid Tumors | Phase 1 | Doma Biopharmaceutical（Suzhou）Co., Ltd. | 48 mi |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Phase 1 | Alterome Therapeutics, Inc. | 48 mi |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors | Phase 1 | TOLREMO therapeutics AG | 48 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | 48 mi |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | 48 mi |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 48 mi |
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1/2 | BioNTech SE | 48 mi |
| FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC | Phase 1/2 | Tubulis GmbH | 48 mi |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Phase 1 | Innate Pharma | 48 mi |
| Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | Phase 1/2 | Phanes Therapeutics | 48 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | Phase 1/2 | Genprex, Inc. | 48 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 48 mi |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | — | Lung Cancer Mutation Consortium | 48 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | 48 mi |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | 48 mi |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | 48 mi |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Phase 1/2 | Frontier Medicines Corporation | 48 mi |
| A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Phase 1/2 | Tyligand Pharmaceuticals (Suzhou) Limited | 48 mi |
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Phase 1 | Amgen | 48 mi |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 48 mi |
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | 48 mi |
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer | Phase 2 | Genmab | 48 mi |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | 48 mi |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. | Phase 2 | Taiho Oncology, Inc. | 48 mi |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | Phase 1/2 | AstraZeneca | 48 mi |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | Phase 2 | Amgen | 48 mi |
| Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | Phase 1 | Nuvectis Pharma, Inc. | 48 mi |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | Arvinas Inc. | 48 mi |
| Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC | Phase 1 | LG Chem | 48 mi |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | 48 mi |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) | Phase 2 | SCRI Development Innovations, LLC | 48 mi |
| A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | 48 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | 48 mi |
| A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | Phase 1 | PAQ Therapeutics, Inc. | 48 mi |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | Phase 1 | Astellas Pharma Inc | 48 mi |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Phase 1 | Sutro Biopharma, Inc. | 48 mi |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Astellas Pharma Global Development, Inc. | 48 mi |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | Phase 1 | ALX Oncology Inc. | 48 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | 48 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | 48 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | 48 mi |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | Phase 1 | Sairopa B.V. | 48 mi |
| First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | Phase 1/2 | Pierre Fabre Medicament | 48 mi |
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers | Phase 1/2 | STORM Therapeutics LTD | 48 mi |
| A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Phase 1 | Incendia Therapeutics | 48 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | 48 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 48 mi |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | 48 mi |
| Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | Phase 2 | Merus B.V. | 48 mi |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Phase 1/2 | Daiichi Sankyo | 48 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | 48 mi |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Eli Lilly and Company | 48 mi |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Phase 2 | Janssen Research & Development, LLC | 48 mi |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Phase 1/2 | OncoResponse, Inc. | 48 mi |
| Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | Phase 1/2 | RedCloud Bio | 48 mi |
| Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 48 mi |
| A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Phase 2 | Merck Sharp & Dohme LLC | 48 mi |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 48 mi |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | 48 mi |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Amgen | 48 mi |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | 48 mi |
| A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Phase 1/2 | Terremoto Biosciences Inc. | 48 mi |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | Phase 3 | ArriVent BioPharma, Inc. | 48 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | 48 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Phase 1 | EvolveImmune United, Inc | 48 mi |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | 48 mi |
| Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | Monte Rosa Therapeutics, Inc | 48 mi |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab | Phase 1 | AbbVie | 48 mi |
| A Study of DF6002 Alone and in Combination With Nivolumab | Phase 1 | Dragonfly Therapeutics | 48 mi |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Phase 2 | Lantern Pharma Inc. | 48 mi |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | Phase 1 | Plexium, Inc. | 48 mi |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | Phase 1 | Novelty Nobility, Inc. | 48 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 48 mi |
| Study of Novel Treatment Combinations in Patients With Lung Cancer | Phase 2 | Gilead Sciences | 48 mi |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Phase 1 | Dren Bio | 48 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | 48 mi |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Phase 1 | Amgen | 48 mi |
| A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) | Phase 1 | Dizal Pharmaceuticals | 48 mi |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 48 mi |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Phase 1/2 | GV20 Therapeutics | 48 mi |
| A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | 48 mi |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | 48 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | 48 mi |
| A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function | Phase 1 | Epizyme, Inc. | 48 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 48 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | 48 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 48 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | 48 mi |
| The Vanguard Study: Testing a New Way to Screen for Cancer | N/A | National Cancer Institute (NCI) | 48 mi |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Coherus Oncology, Inc. | 48 mi |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Phase 2 | AstraZeneca | 48 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | 48 mi |
| A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 48 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | 50 mi |